



Version with markings to show changes made

In the Claims:

Claims 31-39 have been amended as follows:

- A1*
- ~~3421.~~ A cell derived from the transgenic mouse of claim 17, claim 18, claim 19, or claim 20.
- ~~3222.~~ A method of identifying an agent that ameliorates a phenotype associated with a disruption in a CX2 gene, the method comprising:
- (a) administering an agent to a transgenic mouse comprising a disruption in a CX2 gene; and
  - (b) determining whether the agent ameliorates at least one of the following phenotypes : increased body weight, increased body length, or increased body weight to body length ratio as compared to wild-type mice.
- ~~3323.~~ A method of identifying an agent which modulates CX2 expression, the method comprising:
- (a) administering an agent to the transgenic mouse comprising a disruption in a CX2 gene; and
  - (b) determining whether the agent modulates CX2 expression in the transgenic mouse, wherein the agent has an effect on at least one of the following: : increased body weight, increased body length, or increased body weight to body length ratio as compared to wild-type mice.
- ~~3424.~~ A method of identifying an agent which modulates CX2 gene function, the method comprising:
- (a) providing a cell comprising a disruption in a CX2 gene;
  - (b) contacting the cell with an agent; and
  - (c) determining whether the agent modulates CX2 gene function, wherein the agent modulates a phenotype associated with a disruption in a CX2 gene.
- ~~3525.~~ The method of claim ~~3524~~, wherein the phenotype comprises at least one of the following: increased body weight, increased body length, or increased body weight to body length ratio as compared to wild-type mice.
- ~~3726.~~ An agent identified by the method of claim ~~3222~~, claim ~~3323~~, claim ~~3424~~, or claim ~~3525~~.
- ~~3827.~~ An agent that modulates the function, expression or activity of a CX2 gene.
- ~~3928.~~ A method of ameliorating a condition associated with impaired glucose tolerance, the method comprising administering to a subject in need, a therapeutically effective amount of an agent that modulates CX2 function, expression or activity.